[Two decades later, the polypill revisited]

TWO DECADES LATER, THE POLYPILL REVISITED Twenty years later, the promises of the designers of the Polypill are far from being fulfilled. Its effectiveness is still open to debate, while its long-term adverse effects in healthy subjects, particularly due to aspirin, continue to cause concern. Its composition, which varies from one Polypill to another, does not always appear to be as relevant as it would be desirable. In short, it is not certain that its advantages far outweigh its disadvantages. Its validation by the Authorities granting marketing authorizations seems difficult as it stands because it requires demonstrating the benefit of each of its components compared to a placebo and the contribution of each component compared to the others. As for the idea of some of its upholders to make it an over-the-counter drug, it is a headlong rush that is hardly compatible with its target, healthy subjects, and its safety profile.